Cover Page

Cite item


Background: Acute intestinal  infections  in children are a considerable  medical and social problem  worldwide. Immune therapy  could  help  to reduce the frequency of post-infectious functional intestinal dysfunction  in patients  with comorbidities. Aim: To evaluate  the  efficacy of human  recombinant interferon  alpha-2b, administered at acute  phase  of an acute  invasive intestinal  infection to infants in the first months  of age, suffering from functional  bowel  disorders. Materials and methods: This  was  an  open-label,  randomized (envelope method), prospective  study in two parallel groups. The study included  59 infants of the  first months  of life, who were breastfed, had a history of intestinal  dysfunction  and were hospitalized  to  an  infectious  department. We studied  efficacy of recombinant interferon  alpha-2b administered in rectal suppositories  at a dose  of   chromatography with measurement of short-chain fatty acids. Results: Standard treatment was ineffective in 63.3% (95% CI 43.9–80.0%) of patients. Administration   of  interferon   alpha-2b   reduced the rate of treatment failure by day 14 to 32% (95% CI 9–56%) and  the  risk of persistent  diarrhea  for more than  one month  to 29% (95% CI 5–53%). In those patients  who were administered interferon, inflammation at days 25 to 55 was less severe and the levels of i-forms of short-chain fatty acids were lower. Conclusion: Immunotherapy with recombinant interferon alpha-2b seems to be a promising way to improve  combination treatment of acute invasive intestinal infections in infants with a history of intestinal dysfunction, as it reduces the risk of post-infectious intestinal disorders.

About the authors

E. R. Meskina

Moscow Regional Research and Clinical Institute

Author for correspondence.
Meskina Elena R. – MD, PhD,  Professor, Head of Department of Pediatric Infections Russian Federation

E. V. Rusanova

Moscow Regional Research and Clinical Institute

Rusanova Elena V. – PhD, Head of Laboratory of Clinical Microbiology Russian Federation


  1. World Gastroenterology Organisation Global Guidelines. Acute diarrhea in adults and children: a global perspective. World Gastroenterology Organisation, 2012. Доступно на: http:// -diarrhea-in-adults.html (дата обращения: 11.09.2015).
  2. Deising A, Gutierrez RL, Porter CK, Riddle MS. Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas. Gastroenterol Hepatol (N Y).2013;9(3):145–57.
  3. Sandhu BK, Paul SP. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol. 2014;20(20):6013–23. doi: 10.3748/wjg.v20. i20.6013.
  4. Miazga A, Osiński M, Cichy W, Żaba R. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci. 2015;60(1):118–24. doi: 10.1016/j.advms.2014.09.001.
  5. Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Öhman L, Quigley EM, Schmulson M, Sharkey KA, Simrén M. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26(7):1036–48. doi: 10.1111/nmo.12358.
  6. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub- groups of irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(1):31–9. doi: 10.1111/j.1365-2982.2011.01803.x.
  7. Akiba Y, Inoue T, Kaji I, Higashiyama M, Narimatsu K, Iwamoto K, Watanabe M, Guth PH, Engel E, Kuwahara A, Kaunitz JD. Short-chain fatty acid sensing in rat duodenum. J Physiol. 2015;593(3):585–99. doi: 10.1113/jphysiol.2014.280792.
  8. Nakanishi N, Tashiro K, Kuhara S, Hayashi T, Sugimoto N, Tobe T. Regulation of virulence by butyrate sensing in enterohaemorrhagic Escherichia coli. Microbiology. 2009;155(Pt 2):521–30. doi: 10.1099/mic.0.023499-0.
  9. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2010;23(2):366–84. doi: 10.1017/S0954422410000247.
  10. van Tilburg MA, Hyman PE, Walker L, Rouster A, Palsson OS, Kim SM, Whitehead WE. Prevalence of functional gastrointestinal disorders in infants and toddlers. J Pediatr. 2015;166(3):684–9. doi: 10.1016/j.jpeds.2014.11.039.
  11. Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an overview. Food Nutr Bull. 2015;36(1 Suppl):S76–87.
  12. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. Доступно на: http:// w w w.romecr iter omeIII_apA_885-898.pdf (дата обращения: 11.09.2015).
  13. WHO Library Cataloging-in-Publication Data. 2009. Diarrhoea: Why children are still dying and what can be done. The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO); 2009. Доступно на: http:// w w w.unic ef.or g/media/files/Final_Diarrhoea_Report_October_2009_final.pdf (дата обращения: 11.09.2015).
  14. Московский научно-исследовательский институт эпидемиологии и микробиологии МЗ РСФСР. Бактериологическая диагностика дисбактериоза: методические рекомендации. Утверждены Минздравом РСФСР 14.04.1977. М.; 1977. 20 с.
  15. Кондракова ОА, Затевалов АМ, Мазанкова ЛН, Ильина НО, Затевалова ЕА, Гусарова МП, Бабин ВН, Владимирова НП, Холодова ИН, Татищева НБ, Ваулина ОВ. Дисбактериоз кишечника у детей. Определение метаболической активности анаэробной микрофлоры по содержанию летучих жирных кислот в кале и слюне для характеристики дисбиотических состояний кишечника и ротовой полости у детей: пособие для врачей. М.: Прототип; 2005. 56 с.
  16. Гланц С. Медико-биологическая статистика. Пер. с англ. М.: Практика; 1998. 459 с.
  17. Гринхальх Т. Основы доказательной медицины. Пер. с англ. М.: ГЭОТАР-Медиа; 2008. 288 с.
  18. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81(3):1031–64.

Copyright (c) 2015 Meskina E.R., Rusanova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies